Perioperative heparinase rotational thromboelastometry monitoring in adult living related liver transplantation.
Not Applicable
Completed
- Conditions
- Digestive SystemEnd-stage liver disease for scheduled liver transplantation
- Registration Number
- PACTR201712002839259
- Lead Sponsor
- Faculty Medicine, of Menoufia University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
All adult patients with end stage liver disease scheduled for live adult liver transplantation were enrolled within a 2 year study period.
Exclusion Criteria
Any factor that interfere with coagulation such as patient on oral anticoagulant, or on procoagulant as activated factor seven (Novoseven).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clotting Time (CT) of heparinase ROTAM;Maximal Clot Firmness (MCF) of heparinase ROTAM
- Secondary Outcome Measures
Name Time Method Post-operative heparin infusion effect on ROTAM and standard coagulation tests
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does heparinase rotational thromboelastometry target in liver transplantation coagulopathy?
How does heparinase rotational thromboelastometry compare to standard coagulation tests in liver transplant outcomes?
Which biomarkers correlate with heparinase rotational thromboelastometry parameters in end-stage liver disease patients?
What are the potential adverse events associated with heparinase rotational thromboelastometry monitoring during liver surgery?
Are there alternative anticoagulation monitoring strategies for liver transplantation besides heparinase thromboelastometry?